AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Datroway (datopotamab deruxtecan by Year
Datroway (datopotamab deruxtecan — direct product sales) — Worldwide product sales ($M) ($M)
AstraZeneca Datroway (datopotamab deruxtecan: $2M in FY2025.
Where the FY2025 figure comes from
“|| Datroway | 2 | n/m | n/m | - | n/m | 2 | n/m | n/m | - | n/m | n/m | - | n/m | n/m”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Datroway (datopotamab deruxtecan — direct product sales) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | – | Form 6-K FY2025Q4 Earnings Release ↗ |
Breakdown
What makes up datroway (datopotamab deruxtecan
- Datroway (datopotamab deruxtecan — direct product sales) — US product sales ($M)0 · FY2025
- Datroway (datopotamab deruxtecan — direct product sales) — Emerging Markets product sales ($M)2 · FY2025
- Datroway (datopotamab deruxtecan — direct product sales) — Europe product sales ($M)0 · FY2025
- Datroway (datopotamab deruxtecan — direct product sales) — Established RoW product sales ($M)0 · FY2025
Cite this data
StockData. (2026). AstraZeneca Datroway (datopotamab deruxtecan ($M), annual FY2025–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-datroway-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.